Developer docs
API playgroundTry for free, no card

Search company profiles

Will Therapeutics

Full company profile

uuid02lyyrv

Namestring
Will Therapeutics
Legal namestring
Will Therapeutics Inc.
Company typeenum
Private
Founded yearstring
-
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMontreal, Canada
HQ citystring
Montreal
HQ countrystring
Canada
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
small molecule therapeutics, compulsive disorder treatment, central nervous system drugs, anorexia nervosa therapy, acetylcholinesterase inhibitors
Industry2 codes
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAFACAK
Eating Disorder Treatment Programs
Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment
Product category
Biopharmaceuticals
No data
Revenue model1 record
1Drug Development and Commercialization
TypeOne Time License
Description

Pre-revenue biotech company developing a novel therapeutic compound for anorexia nervosa and related compulsive disorders. Revenue model not yet established as the company is in pre-clinical/early clinical stage of drug development.

willtherapeutics.com
Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Will Therapeutics develops a brain-penetrant small molecule acetylcholinesterase inhibitor protodrug designed to restore dopamine balance in the striatum neural pathway that drives compulsive behavior. The lead program targets anorexia nervosa as the initial indication, with pipeline expansion planned into obsessive compulsive disorder, addiction disorders, tics/Tourette's, body-focused repetitive behaviors, and other eating disorders.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 0 approved drugs for anorexia nervosa vs 15 approved for cervical cancer with similar mortality
+1 more record
Product overview1 text field

Will Therapeutics is a biopharmaceutical company developing a single core therapeutic compound—a brain-penetrant small molecule acetylcholinesterase inhibitor protodrug. The company focuses on treating anorexia nervosa as its initial indication, with pipeline opportunities for obsessive compulsive disorder, phone/social media addiction, gambling addiction, tics/Tourette's, body-focused repetitive behaviors (BFRBs), rigid behaviors in autism, and other eating disorders. The compound is designed to restore dopamine balance in the striatum, a neural pathway central to habit and compulsion, representing a targeted biological approach rather than behavioral management.

Product and service1 record
1Brain-Penetrant Acetylcholinesterase Inhibitor Protodrug
Partnership1 partner
1Quebec Consortium for Drug Discovery
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research grant awarded by the Quebec Consortium for Drug Discovery supporting the company's translational science program combining preclinical validation, human signal, and molecular redesign for the treatment of compulsive disorders.

willtherapeutics.com
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage CNS biotech developing therapies for psychiatric conditions; comparable as a small-molecule/circuit-targeted biotech addressing high-need psychiatric indications where few treatment options exist.

TypeDirect peer
Description

CNS-focused biopharma pioneering targeted neuromodulators for serious psychiatric and neurological disorders, including Zurzuvae; closely comparable in modality and stage of CNS drug development.

TypeDirect peer
Description

Commercial-stage CNS biopharma with Auvelity and other CNS therapeutics in psychiatry; relevant as a small-molecule CNS commercializer advancing therapies for underserved psychiatric conditions.

TypeEmerging player
Description

Neuroscience-focused biopharmaceutical company with a portfolio of CGRP-targeting and other neurology/psychiatry assets; comparable as a CNS specialty player pursuing differentiated mechanisms for serious brain disorders.

TypeDirect peer
Description

Developed xanomeline-based therapies for schizophrenia and related conditions, illustrating a precedent of circuit-driven CNS small molecules advancing in psychiatric indications; structurally similar biotech archetype.

TypeDirect peer
Description

Clinical-stage neuroscience company developing brain-targeted therapies for neuropsychiatric and neurodegenerative conditions; analogous as a biology-driven, CNS-focused private biotech.

TypeBroad incumbent
Description

CNS-focused biopharma with Caplyta approved for schizophrenia and bipolar depression; comparable as an established specialty CNS developer with multiple psychiatric indications.

TypeDirect peer
Description

Neuroscience biopharma developing precision small molecules for CNS disorders; directly comparable as a circuit-targeted, brain-penetrant small-molecule CNS developer.

TypeBroad incumbent
Description

Established CNS biopharma commercializing therapies for neuropsychiatric conditions such as Parkinson's psychosis and Rett syndrome; a broader incumbent in the same specialty prescription CNS space.

TypeBroad incumbent
Description

Biopharmaceutical company specializing in engineering brain-penetrant therapeutics, including enzyme inhibitors for CNS disorders; directly comparable on brain-targeted delivery platform and neurodegeneration/neuropsychiatry focus.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Will Therapeutics

Biopharmaceuticalswilltherapeutics.com

Will Therapeutics firmographics

Firmographics
Name
Will Therapeutics
Legal name
Will Therapeutics Inc.
Website
https://willtherapeutics.com
Company type
Private
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Will Therapeutics industry classification

Industry
Product category
Biopharmaceuticals
akta.pro industry
PRIMARYHLAIALAB
Lead Optimization & Preclinical Candidate Selection
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAFACAK
Eating Disorder Treatment Programs
Healthcare & Life Sciences/Healthcare Providers & Systems/Behavioral Health & Substance Use Treatment

Keywords

  • Small molecule therapeutics
  • Compulsive disorder treatment
  • Central nervous system drugs
  • Anorexia nervosa therapy
  • Acetylcholinesterase inhibitors

Where Will Therapeutics is headquartered

Location

Headquarters

HQ city
Montreal
HQ country
Canada
HQ region
North America

Offices1 record

Markets served

Will Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Drug Development and Commercialization: Pre-revenue biotech company developing a novel therapeutic compound for anorexia nervosa and related compulsive disorders. Revenue model not yet established as the company is in pre-clinical/early clinical stage of drug development.

Will Therapeutics product offering

Product offering

Core offering

Will Therapeutics develops a brain-penetrant small molecule acetylcholinesterase inhibitor protodrug designed to restore dopamine balance in the striatum neural pathway that drives compulsive behavior. The lead program targets anorexia nervosa as the initial indication, with pipeline expansion planned into obsessive compulsive disorder, addiction disorders, tics/Tourette's, body-focused repetitive behaviors, and other eating disorders.

Product overview

Will Therapeutics is a biopharmaceutical company developing a single core therapeutic compound—a brain-penetrant small molecule acetylcholinesterase inhibitor protodrug. The company focuses on treating anorexia nervosa as its initial indication, with pipeline opportunities for obsessive compulsive disorder, phone/social media addiction, gambling addiction, tics/Tourette's, body-focused repetitive behaviors (BFRBs), rigid behaviors in autism, and other eating disorders. The compound is designed to restore dopamine balance in the striatum, a neural pathway central to habit and compulsion, representing a targeted biological approach rather than behavioral management.

Differentiator

Problem solved

Functional benefit

Products and services

  • Brain-Penetrant Acetylcholinesterase Inhibitor Protodrug

Quantifiable outcome

  • 0 approved drugs for anorexia nervosa vs 15 approved for cervical cancer with similar mortality
  • +1 more outcomes

Companies that use Will Therapeutics

Customer profile

Segments1 record

Ideal customer profiles2 records

Will Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Will Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Quebec Consortium for Drug DiscoverycoreStrategic or Co-development PartnerResearch grant awarded by the Quebec Consortium for Drug Discovery supporting the company's translational science program combining preclinical validation, human signal, and molecular redesign for the treatment of compulsive disorders.

Recent moves5 records

Expansion highlights4 records

Will Therapeutics competitors and assessment

Company assessment

Direct peers

  • COMPASS Pathways: Clinical-stage CNS biotech developing therapies for psychiatric conditions; comparable as a small-molecule/circuit-targeted biotech addressing high-need psychiatric indications where few treatment options exist.
  • Sage Therapeutics: CNS-focused biopharma pioneering targeted neuromodulators for serious psychiatric and neurological disorders, including Zurzuvae; closely comparable in modality and stage of CNS drug development.
  • Axsome Therapeutics: Commercial-stage CNS biopharma with Auvelity and other CNS therapeutics in psychiatry; relevant as a small-molecule CNS commercializer advancing therapies for underserved psychiatric conditions.
  • Karuna Therapeutics: Developed xanomeline-based therapies for schizophrenia and related conditions, illustrating a precedent of circuit-driven CNS small molecules advancing in psychiatric indications; structurally similar biotech archetype.
  • Neumora Therapeutics: Clinical-stage neuroscience company developing brain-targeted therapies for neuropsychiatric and neurodegenerative conditions; analogous as a biology-driven, CNS-focused private biotech.
  • Cerevel Therapeutics: Neuroscience biopharma developing precision small molecules for CNS disorders; directly comparable as a circuit-targeted, brain-penetrant small-molecule CNS developer.

Emerging players

  • Biohaven Pharmaceuticals: Neuroscience-focused biopharmaceutical company with a portfolio of CGRP-targeting and other neurology/psychiatry assets; comparable as a CNS specialty player pursuing differentiated mechanisms for serious brain disorders.

Broad incumbents

  • Intra-Cellular Therapies: CNS-focused biopharma with Caplyta approved for schizophrenia and bipolar depression; comparable as an established specialty CNS developer with multiple psychiatric indications.
  • Acadia Pharmaceuticals: Established CNS biopharma commercializing therapies for neuropsychiatric conditions such as Parkinson's psychosis and Rett syndrome; a broader incumbent in the same specialty prescription CNS space.
  • Denali Therapeutics: Biopharmaceutical company specializing in engineering brain-penetrant therapeutics, including enzyme inhibitors for CNS disorders; directly comparable on brain-targeted delivery platform and neurodegeneration/neuropsychiatry focus.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Will Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Will Therapeutics leadership team

Management profile

Number of profiles

Will Therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Will Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Will Therapeutics

What does Will Therapeutics do?

Will Therapeutics develops a brain-penetrant small molecule acetylcholinesterase inhibitor protodrug designed to restore dopamine balance in the striatum neural pathway that drives compulsive behavior. The lead program targets anorexia nervosa as the initial indication, with pipeline expansion planned into obsessive compulsive disorder, addiction disorders, tics/Tourette's, body-focused repetitive behaviors, and other eating disorders.

Is Will Therapeutics a public or private company?

Will Therapeutics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Will Therapeutics founded?

Will Therapeutics was founded in -1. It employs 1 to 10 people.

Where is Will Therapeutics based?

Will Therapeutics is headquartered in Montreal, Canada, in the North America region.

How does Will Therapeutics make money?

One revenue line is on record: drug Development and Commercialization.

Who are Will Therapeutics's main competitors?

Direct peers on record are COMPASS Pathways, Sage Therapeutics, Axsome Therapeutics, Karuna Therapeutics, Neumora Therapeutics and Cerevel Therapeutics. Biohaven Pharmaceuticals is listed as an emerging player. Broad incumbents are Intra-Cellular Therapies, Acadia Pharmaceuticals and Denali Therapeutics.

Does Will Therapeutics have an API?

No public API is recorded for Will Therapeutics.

What industry is Will Therapeutics in?

Will Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAIALAB, Lead Optimization & Preclinical Candidate Selection, with a secondary code of HLAFACAK, Eating Disorder Treatment Programs.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales